ClinicalTrials.gg
Enrolling by invitationNCT06722443MicoBeBioticosUpdated Apr 11, 2025

Impact of Nutritional Intervention With Probiotics and Prebiotics on Obesity.

An interventional study of Probiotic and Prebiotic in Obesity and Overweight, Obesity, Morbid and Metabolic Syndrome, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Obesity, Morbid with a site in Spain — 11 open to participants now, 14 under way, 1 of them phase 3. Obesity, Morbid · Spain.

Planned enrollment
3rd of 25
230 · median 68
Started
2024
with 2 others
No phase
22 of 38
5 open now
Primary completion
2025-03
later than 3 of 13 live
Registered
33rd of 38
by date

Among the 38 studies in Obesity, Morbid with a site in Spain, this one is the 3rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 22 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 33rd registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

11 of the 38 studies in Obesity, Morbid with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Obesity, Morbid with a site in Spain, or all of them as a file.
02

Study summary

Obesity is one of the most severe and prevalent non-communicable diseases worldwide, affecting an estimated one-third of the population in Spain. It is a multifactorial disease that, in extreme cases such as morbid obesity, can become highly disabling and is associated with significant morbidity and mortality. This is because it serves as a risk factor for numerous chronic diseases, including metabolic conditions (type 2 diabetes mellitus), cardiovascular diseases (hypertension, atherosclerosis, etc.), and even cancer.

The exact etiopathogenic mechanisms are not fully understood, but subclinical inflammation is considered to form the basis of the metabolic (diabetes) and cardiovascular (endothelial dysfunction, dyslipidemia, etc.) disturbances that almost invariably accompany obesity. Additionally, alterations in the composition of the gut microbiota, or dysbiosis, are now recognized as playing a key role in the pathogenesis of obesity. This makes the gut microbiota a highly attractive therapeutic target for both the prevention and treatment of obesity, including less severe forms and morbid obesity.

In this context, the use of probiotics or extracts with prebiotic properties represents a particularly interesting strategy against obesity, offering a combination of efficacy and safety for treating these patients. Consequently, the general objective is proposed to evaluate the impact of dietary interventions aimed at modulating dysbiosis through the administration of a probiotic (Lactobacillus fermentum CECT5716), a standardized olive leaf extract with prebiotic properties, or a synbiotic (a combination of the olive leaf extract and L. fermentum CECT5716) on the clinical response of patients with moderate or morbid obesity. This will include determining its relationship with the immuno-metabolic system and the characteristic cardiovascular complications of obesity.

Furthermore, the evaluation of these treatments in experimental models of obesity, including morbid obesity requiring surgery, is also proposed. These models will include trials involving fecal material transfer into germ-free mice. These results will add significant value to the project by advancing our understanding of the underlying mechanisms of the disease. This will aid in the establishment of new diagnostic, prognostic, and therapeutic biomarkers, which are of great interest in reducing the incidence and prevalence of this current obesity epidemic.

The estimated duration for completing the project is 12 months, with its conclusion anticipated by March 2024.

Read the detailed description

Obesity: The Epidemic of the 21st Century and a Public Health Concern. Obesity is one of the most severe and prevalent non-communicable diseases of the 21st century, representing a global public health problem that affects all age groups. In Spain, it is estimated that over 39% of adults (aged 25-60) are overweight and 20% are obese, with Andalusia being one of the regions with the highest rates, which continue to rise. Obesity is a multifactorial, recurrent, and progressive disease associated with significant physical and psychological complications, as well as considerable morbidity and mortality. It is a key risk factor for numerous chronic conditions, including metabolic syndrome (type 2 diabetes mellitus, hypertension, dyslipidemia) and the associated elevated risk of cardiovascular diseases.

Moreover, obesity can increase the risk of other diseases, including digestive, respiratory, and joint disorders, as well as various types of cancer (esophagus, colon, pancreas, prostate, and breast). Although the pathogenic mechanisms underlying obesity are not fully elucidated, it is understood that obesity is linked to a state of chronic low-grade systemic inflammation. Dysregulated adipose tissue functionality in obese individuals leads to elevated free fatty acid levels and increased production of inflammatory cytokines, establishing a vicious cycle that promotes the hypertrophy and hyperplasia of adipocytes, hallmarks of obesity.

The excessive production of these mediators and their release into the bloodstream have a profound impact on other organs and systems, contributing to the metabolic (e.g., diabetes) and cardiovascular (e.g., endothelial dysfunction, atherosclerosis) alterations that almost invariably accompany obesity. Consequently, obesity is associated with reduced quality of life and has a significant negative socioeconomic impact. It is also a determinant of several "intermediate risk factors," leading to increased mortality and reduced life expectancy.

The treatment of obesity involves lifestyle and dietary changes, often supplemented by pharmacological therapy, including appetite suppressants and fat absorption inhibitors. However, these strategies may be insufficient, and for severe obesity (BMI >35) or morbid obesity (BMI >40), surgical intervention is often necessary. Bariatric surgery, despite its effectiveness in reducing metabolic and cardiovascular comorbidities and improving survival and quality of life, involves significant complications due to patient characteristics and high costs. Moreover, over the last 30 years, there has been a marked increase in the prevalence of morbid obesity and, consequently, a greater demand for bariatric surgery.

While surgery reduces comorbidities and enhances patient outcomes, its effects on the gut microbiota remain suboptimal. As such, specific dietary interventions before and/or after surgery are needed to improve microbial gene richness and ensure long-term metabolic health.

The Gut Microbiome as a Modifiable Factor in Obesity. Numerous studies have highlighted the critical role of the gut microbiome in the development and maintenance of obesity and its associated conditions. Research shows that the microbiome composition in lean individuals differs significantly from that in obese individuals, a condition known as dysbiosis. Obese individuals exhibit an increased Firmicutes/Bacteroidetes ratio, reduced microbial diversity, and enhanced energy extraction efficiency from food.

Dysbiosis is also associated with increased intestinal permeability, allowing bacterial components such as lipopolysaccharides (LPS) to enter systemic circulation, which promotes endotoxemia and exacerbates inflammation. This altered microbial composition is linked to increased production of short-chain fatty acids (SCFAs), particularly propionate, which may contribute to lipogenesis and gluconeogenesis.

Severe dysbiosis is observed in morbidly obese patients, characterized by drastic reductions in microbial richness, intensified systemic inflammation, and metabolic disturbances. Although bariatric surgery improves weight, metabolic markers, and microbial diversity, it does not restore microbiota richness to levels observed in lean individuals. Therefore, dietary interventions targeting microbial restoration are critical for post-surgical recovery and long-term health.

Modulation of the Microbiome in Obesity: Probiotics and Prebiotics. The selective modulation of the gut microbiome using probiotics and prebiotics has emerged as a promising therapy for obesity. Probiotics, defined as live microorganisms that confer health benefits when administered in adequate amounts, offer several advantages, including strengthening the intestinal barrier, immunomodulation, and restoring dysbiosis. Commonly used probiotics in obesity management include strains from the Lactobacillus and Bifidobacterium genera.

Studies in both animal models and humans have demonstrated that specific strains can reduce body weight, fat accumulation, lipid profiles, and inflammatory markers. However, the overall efficacy in humans has been modest, necessitating further research to identify optimal strains, dosages, and treatment durations.

Lactobacillus fermentum CECT5716 has shown immunomodulatory properties in experimental models of colitis and hypertension. Preliminary unpublished studies suggest that it can reduce weight gain and systemic inflammation in obesity models, likely by improving dysbiosis and intestinal barrier function.

Prebiotics, non-digestible dietary components that selectively stimulate beneficial gut bacteria, are also effective in obesity management. Phenolic compounds, such as oleuropein from olive leaves, have shown significant prebiotic potential, reducing fat deposition, improving lipid and glucose profiles, and mitigating inflammation and vascular dysfunction in animal studies.

The current project aims to evaluate the effects of dietary supplementation with L. fermentum CECT5716 or a standardized olive leaf extract, alone or in combination, on clinical outcomes in patients with moderate and morbid obesity. Specifically, it will assess their impact on dysbiosis, metabolic and cardiovascular health, and post-surgical recovery in morbidly obese patients. The intervention's effectiveness will be correlated with adherence to a Mediterranean diet. By integrating microbiomic and metabolomic analyses, the study seeks to establish a personalized treatment framework for obesity.

H1: L. fermentum CECT5716 and/or olive leaf extract supplementation reduces inflammation, metabolic disturbances, and cardiovascular complications in obesity.

H2: These interventions restore dysbiotic gut microbiota composition and function.

H3: Supplementation improves post-operative outcomes in morbidly obese patients.

H4: Combining probiotic and prebiotic interventions provides synergistic benefits, maximizing efficacy.

This project offers a comprehensive approach to addressing obesity through microbiome modulation, paving the way for innovative, personalized therapeutic strategies.

03

Conditions studied

  • Obesity and Overweight
  • Obesity, Morbid
  • Metabolic Syndrome

Browse trials for

Keywords

  • microbiome
  • obesity
  • metabolic syndrome
  • probiotics
  • prebiotics
  • symbiotics
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 230 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical Diagnosis of Obesity and Associated Comorbidities (Prediabetes, Diabetes, Dyslipidemia, Hypertension).

Exclusion criteria

Exclusion Criteria:

  • Antibiotic treatment.
  • Pregnancy.
  • Clinical diagnoses of Inflammatory bowel disease.
  • Clinical diagnosis of Celiac disease
  • Clinical diagnosis of Hematological pathologies.
  • Clinical diagnosis of or immunodeficiency diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
230 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo treated with 500 mg/capsule/day of maltodextrin

    Dietary Supplement: Probiotic · Dietary Supplement: Prebiotic · Dietary Supplement: Synbiotic

  • Active comparator
    Probiotic

    capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716

    Dietary Supplement: Prebiotic · Dietary Supplement: Synbiotic

  • Active comparator
    Prebiotic

    500 mg/capsule/day of olive leaf extract, containing 35% oleuropein, an amount comparable to what could be consumed through daily intake of extra virgin olive oil.

    Dietary Supplement: Probiotic · Dietary Supplement: Synbiotic

  • Active comparator
    Symbiotic

    A combination of prebiotic and probiotic at the same doses.

    Dietary Supplement: Probiotic · Dietary Supplement: Prebiotic

Interventions

  • Dietary supplementProbiotic

    Treatment with capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716 during 6 months

  • Dietary supplementPrebioticsStudies of PrebioticsPrebiotics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment with capsules 500 mg/capsule/day of olive leaf extract, containing 35% oleuropein during 6 months

  • Dietary supplementSynbiotic

    A pill with a combination of prebiotic and probiotic at the same doses during 6 months

07

What researchers measure

Primary outcomes

  1. Evaluation of the composition of the intestinal microbiome using metagenomic analysis

    Microbial DNA will be isolated from the intestinal contents (feces) of different groups at various time points (T0 and T6). Taxonomic group identification will be performed through metagenomic sequencing using the Nextera XT Library Preparation Kit (Illumina). Sequencing will be conducted on a NovaSeq-6000 platform. To analyze the microbiota taxonomy, the RAST platform will be used to classify reads into different amplicon sequence variants (ASVs). A dynamic threshold will be applied to filter out false or incorrect ASVs, eliminating those contributing less than 0.1% of the total sequence count. The ASVs table will then be normalized per sample using subsampling (or rarefaction) to a minimum read count. QIIME wrapper scripts (v1.9.1) will be employed to classify reads into taxonomic units and to identify taxa with differential abundance between groups.

    Time frame: From enrollment (T0) to the end of treatment (6 months(T6))

  2. Evaluation of the treatment using integrated data analysis

    The data obtained from the different determinations conducted will be automated for integrated analysis. Variables will be normalized, and qualitative variables will be categorized. Integrated bioinformatics analysis will compare and functionally correlate nutritional data, omics data (microbiomics, metabolomics, and immunological profiles) with clinical phenotypes (obese and morbidly obese patients) and treatments (probiotic, prebiotic, and synbiotic). This analysis will be based on Bayesian methods, which provide a statistical framework enabling the probabilistic integration of information across multiple analysis steps. All data will be analyzed using R and GraphPad Prism (version 8.4.1). This approach will allow the identification of relationships between microbiota impact and the administered treatments, as well as determine which treatment demonstrated the highest efficacy.

    Time frame: From enrollment (T0) to the end of treatment (6 months(T6))

Secondary outcomes

  1. Evaluation of serological biochemical profile

    In blood samples collected at different points of the study (baseline and endpoint), the following parameters will be assessed using an autoanalyzer (Beckman Coulter AU5800): serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and γ-glutamyl transpeptidase (GGT), total bilirubin, creatinine, uric acid, and lipid profile, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL). Serum leptin, IL-6, and TNF-α will be measured using the MILLIPLEX MAG Human Adipokine Magnetic Bead Panel (Millipore). Serum adiponectin, lipopolysaccharide-binding protein (LBP), and insulin will be quantified using ELISA kits. All variables will be quantified in IU/L.

    Time frame: From enrollment to the end of treatment (6 months)

  2. Determination of the treatment impact on the metabolome profile

    Metabolomic studies from serum samples at two different points (initial and final point) will be performed usign HPLC-GS-GC (min and m/z).

    Time frame: From enrollment (T0) to the end of treatment (6 months(T6))

08

Study locations

1 site
  • Centro de Investigacion Biomedica
    Granada, 18016, Spain
09

References and documents

Publications

  • Rodriguez-Sojo MJ, Ruiz-Malagon AJ, Hidalgo-Garcia L, Molina-Tijeras JA, Diez-Echave P, Lopez-Escanez L, Rosati L, Gonzalez-Lozano E, Cenis-Cifuentes L, Garcia-Garcia J, Garcia F, Robles-Vera I, Romero M, Duarte J, Cenis JL, Lozano-Perez AA, Galvez J, Rodriguez-Cabezas ME, Rodriguez-Nogales A. The Prebiotic Effects of an Extract with Antioxidant Properties from Morus alba L. Contribute to Ameliorate High-Fat Diet-Induced Obesity in Mice. Antioxidants (Basel). 2023 Apr 21;12(4):978. doi: 10.3390/antiox12040978. PubMed 37107352 ↗
  • Diez-Echave P, Vezza T, Algieri F, Ruiz-Malagon AJ, Hidalgo-Garcia L, Garcia F, Moron R, Sanchez M, Toral M, Romero M, Duarte J, Garrido-Mesa J, Rodriguez-Cabezas ME, Rodriguez-Nogales A, Galvez J. The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome. Biomed Pharmacother. 2022 Sep;153:113445. doi: 10.1016/j.biopha.2022.113445. Epub 2022 Jul 22. PubMed 36076560 ↗
  • Molina-Tijeras JA, Diez-Echave P, Vezza T, Hidalgo-Garcia L, Ruiz-Malagon AJ, Rodriguez-Sojo MJ, Romero M, Robles-Vera I, Garcia F, Plaza-Diaz J, Olivares M, Duarte J, Rodriguez-Cabezas ME, Rodriguez-Nogales A, Galvez J. Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis. Pharmacol Res. 2021 May;167:105471. doi: 10.1016/j.phrs.2021.105471. Epub 2021 Jan 30. PubMed 33529749 ↗
  • Vezza T, Rodriguez-Nogales A, Algieri F, Garrido-Mesa J, Romero M, Sanchez M, Toral M, Martin-Garcia B, Gomez-Caravaca AM, Arraez-Roman D, Segura-Carretero A, Micol V, Garcia F, Utrilla MP, Duarte J, Rodriguez-Cabezas ME, Galvez J. The metabolic and vascular protective effects of olive (Olea europaea L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties. Pharmacol Res. 2019 Dec;150:104487. doi: 10.1016/j.phrs.2019.104487. Epub 2019 Oct 11. PubMed 31610229 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Mar 2025, 13 months.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 13 months is below that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2024
First posted
Dec 9, 2024
StartActual
Feb 1, 2024
Primary completionActual
Mar 1, 2025
CompletionEst.
May 1, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06722443
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Responsible party
Alba Rodriguez Nogales (Full professor, Universidad de Granada) — Principal investigator
First posted
Dec 9, 2024
Start date
Feb 1, 2024
Primary completion
Mar 1, 2025
Completion
May 1, 2025 (estimated)
Last update
Apr 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion